References

6 downloads 73 Views 201KB Size Report
In: Wintrobe's Clinical Hematology. .... principles and practice of hematology first ed., JB lippincott .... in wintrob's clinical hematology, ninth edition : Lee GR,.


REFERENCES

References 1-

Aarabi B, Haghshenas M and Rakeii V. (1998): Visual failure caused by suprasellar extramedullary hematopoiesis in beta thalassemia: case report. Neurosurgery;42:922–925.

2-

Aessopos A, Farmakis D and Loukopoulos D. (2002): Elastic tissue abnormalities resembling pseudoxanthoma elasticum in beta thalassemia and the sickling syndromes. Blood;99:30–35.

3-

Allen SJ, O'Donnell A and Alexander ND. (1997): alpha+Thalassemia protects children against disease caused by other infections as well as malaria. Proc Natl Acad Sci U S A;94:14736–14741.

4-

Amer J and Fibach E. (2004): Oxidative status of platelets in normal and thalassemic blood. Thromb Haemost;92:10529.

5-

American Diabetes Association (2003): Standards of medical care for patients with diabetes mellitus (position statement). Diabetes Care; 26 (1): S33- S61.

6-

American Diabetes Association (ADA, 2005). Diagnosis and Classification of Diabetes Mellitus. Diabetes Care; 28 (suppl1) : S37-S42.

7-

Anderson LJ, Wonke B, Prescott E, Holden S, Walker JM and Pennell DJ. (2002): Comparison of effects of oral deferiprone

and

subcutaneous

106

desferrioxamine

on



REFERENCES myocardial iron concentrations and ventricular function in beta-thalassemia. Lancet;360: 516-20.

8-

Andreani M, Nesci S and Lucarelli G. (2000): Long-term survival of ex-thalassemic patients with persistent mixed chimerism after bone marrow transplantation. Bone Marrow Transplant ;25:401-4.

9-

Angastiniotis

M

and

Modell

B.

(1998):

Global

epidemiology of hemoglobin disorders. Ann N Y Acad Sci;850:251-9. 10-

Angastiniotis M, Pavlides N and Aristidou K. (1998): Bone pain in thalassaemia: assessment of DEXA and MRI findings. J Pediatr Endocrinol Metab;11[Suppl 3]:779–784.

11-

Angelucci E, Bai H and Centis F. (2002): Enhanced macrophagic

attack

on

β-thalassemia

major

erythroid

precursors. Haematologica;87:578-83.

12-

Arrigo T, Crisafulli G, Meo A, Sturiale M, Lombardo F, Miceli M, Cucinotta D and De Luca F. (1998): Glucose tolerance, insulin secretion and peripheral sensitivity in thalassaemia major. J Pediatr Endocrinol Metab;11 (Suppl. 3):863– 866.

13-

Atweh GF and Loukopoulos D. (2001): Pharmacological induction of fetal hemoglobin in sickle cell disease and bthalassemia. Semin Hematol; 38:367-73.

107



REFERENCES

. 14-

Aydinok Y, Dacran S, Polat A, Kavaklik NG, Coker M, Katner M and centigul N (2002): Endocrine complications of patients with β-thalassemia major. J Trop Pediatr; 48: 50 – 54.

15-

Belfiore F., Iannello S., Volpicelli G.: Insulin sensitivity indices calaulated from basal and OGGT-induced insulin, glucose and FFA levels.Mol Genet Metab. 1998;63:134-141.

16-

Benz

EF

and

Giardina

PTV

(1995):

Thalssemia

syndromes. In:Blood disease of infancy and childhood Miller DR and Bachner RL(eds) seventh Edition Mosby year book,p.160. 17-

Beris

P

(1995):

Thalassemia

management.

Semin

Hematol; 32: 243- 313. 18-

Bhanu NV, Trice TA, Lee YT and Miller JL. (2004): A signaling mechanism for growth-related expression of fetal hemoglobin. Blood; 103:1929-33.

19-

Blake DR, Meigs JB, Muller DC, Najjar SS, Andres R and Nathan DM. (2004): Impaired glucose tolerance, but not impaired fasting glucose, is associated with increased levels of coronary heart disease risk factors: results from the Baltimore Longitudinal Study on Aging. Diabetes;53(8):2095100.

108

 20-

REFERENCES Bolli GB (2003): Insulin treatment and complications. In; Textbook of Diabetes. Pickup JC, and Williams G (eds). Blackwell Science, 3rd ed; 37: 1-19.

21-

Borgna-Pignatti C, Carnelli V and Caruso V. (1998): Thromboembolic events in beta thalassemia major: an Italian multicenter study. Acta Haematol;99:76–79.

22-

Bradai M, Abad MT, Pissard S, Lamraoui F, Skopinski L, de and Montalembert M. (2003): Hydroxyurea can eliminate transfusion

requirements

in

children

with

severe

β-

thalassemia. Blood;102: 1529-30. 23-

Braude P, Pickering S, Flinter F and Ogilvie CM. (2002): Preimplantation genetic diagnosis. Nat Rev Genet;3:941-53.

24-

Buchanan TA and Xiang AH. (2005): Gestational diabetes mellitus. J Clin Invest;115(3):485-91.

25-

Butthep P, Bunyaratvej A and Funahara Y. (1995): Alterations

in

vascular

endothelial

cell-related

plasma

proteins in thalassaemic patients and their correlation with clinical symptoms. Thromb Haemost; 74:1045–1049.

26-

Cao A, Galanello R and Rosatelli MC. (1996): Clinical experience of management of thalassaemia: the Sardinian experience. Semin Hematol;1:66–75.

27-

Cappellini MD, Robbiolo L, Bottasso BM, Coppola R,

109



REFERENCES Fiorelli

G,

and

Mannucci

AP.

(2000):

Venous

thromboembolism and hypercoagulability in splenectomized patients

with

thalassaemia

intermedia.

Br

J

Haematol;111:467-73. 28-

Cario

H,

Holl

RW

and

Debatin

KM

(2003):

Disproportionately elevated fasting proinsulin levels in normglycemic patients with thalassemia major are correlated to the degree of iron overload. Horm Res; 59: 73-78. 29-

Cario H, Holl RW and Debatin KM (2003): Insulin sensitivity and beta-cell secretion in thalassmia major with secondary haemochromatosis : assessment by oral glucose tolerance test .Eur J Pediatr 2003 :162: 139-146

30-

Caterina BP and Renzo G (2004):Thalassemias and Related Disorders: Quantitative Disorders of Hemoglobin Synthesis. In: Wintrobe's Clinical Hematology. Chapter 42John P. Greer, John Foerster, John N. Lukens, George M. Rodgers, Frixos Paraskevas, and Bertil Glader (eds). Lippincott Williams & Wilkins, pp 1052-1075.

31-

Cavallo-Perin P, Pacini G, Cerutti F, Bessone A, Condo C, Sacchetti L, Pica A and Pagano G. (1995): Insulin resistance

and

hyperinsulinemia

in

homozygous

b-

thalassemia. Metabolism; 44:281–286. 32-

Ceci A, Baiardi P and Felisi M. (2002): The safety and effectiveness of deferiprone in a large-scale, 3-year study in

110



REFERENCES Italian patients. Br J Haematol;118:330-6.

33-

Centis F, Tabellini L and Lucarelli G. (2000): The importance of erythroid expansion in determining the extent of apoptosis in erythroid precursors in patients with βthalassemia major. Blood;96:3624-9.

34-

Chao TH and Wang B (1996):The correlation of srum ferritin to Ca/p metabolisms and bone density study in thalassemic patients. J Pediatr Endocrinol Metab., 9(6):809-4.

35-

Chern JP, Lin KH, Lu MY and Lin DT (2001): Abnormal glucose tolerance in transfusion dependant β-thalassemic patients. Diabetes Care; 24: 850- 854.

36-

Cherrington AD. (1999): Control of glucose uptake and release by the liver in vivo. Diabetes; 48:1198–214.

37-

Cianciulli P, Sorrentino F and Maffei L. (2002): Cardiovascular involvement in thalassemic patients with PXE-like skin lesions. A long term follow up study. Eur J Clin Invest;32: 700–706.

38-

Cighetti G, Duca L and Bortone L. (2002): Oxidative status and malondialdehyde in b-thalassemia patients. Eur J Clin Invest ;32: Suppl 1:55-60.

39-

Cohen AR, Galanello R and Pennell DJ. (2004): Thalassemia. Hematology (Am Soc Hematol Educ Program);

111



REFERENCES 14-34

40-

Cooley TB and Lee P. (1925) A series of cases of splenomegaly in children with anemia and peculiar bone changes. Trans Am Pediatr Soc;37:29-30.

41-

Cunningham MJ, Macklin EA, Neufeld EJ and Cohen AR. (2004): Complications of β-thalassemia major in North America. Blood; 104:34-9.

42-

Dawson

SB and Trapp R (1994): Basic and clinical

biostatistics in: Lange Medical Book 2nd edition, prentice – Hall International Inc; 201-205. 43-

De Sanctis V, Savarino L and Stea S. (2000): Microstructural analysis of severe bone lesions in seven thalassemic patients treated with deferoxamine. Calcif Tissue Int;67:128–133.

44-

De Sanctis V, Zurlo MG and Senesi E (1988): Insulindependant diabetes in thalassemia. Arch Dis Child; 63: 5862.

45-

De Sanctis V. (2002):

Growth and puberty and its

management in thalassaemia. Horm Res;58:Suppl 1:72-9. 46-

Di Naro E, Ghezzi F and Vitucci A. (2000): Prenatal diagnosis of b-thalassemia using fetal erythroblasts enriched from maternal blood by a novel gradient. Mol Hum Reprod; 6:571-4.

112

 47-

REFERENCES Ding C, Chiu RWK and Lau TK. (2004): MS analysis of single-nucleotide differences in circulating nucleic acids: application to noninvasive prenatal diagnosis. Proc Natl Acad Sci USA;101 :10762-7.

48-

Dmochowski K, Finegood DT and Tayler B (1993): Factors determining glucose tolerance in patients with thalassemia major. J Clin Endocrinol Metabol;77: 478- 483.

49-

El-Beshlawy A (2005): Highlights on prevention and clinical issue on thalassemia management in Egypt, sixth International

Conference, Update in Thalassemia (From

prevention to gene therapy, Cairo,Egypt,p 21-22. 50-

El-Beshlawy A., Salama KM.,Salama HM.,Makhlouf A.,Mohamed SI (2003): Study of blood levels of glucose and insulin

in

Egyptian

thalassemics

not

known

to

be

diabetics.Med J Cairo Univ. ; 71(2):21-27. 51-

El- Hazemi MA, Al-Swailem I, Al-Fawaz A and Warsey AS (1994): Diabetes mellitus in children suffering from beta thalassemia. J Trop Pediatr; 40: 261- 266

52-

Eldor

A

and

Rachmilewitz

EA.

(2002):

The

hypercoagulable state in thalassemia. Blood; 99:36-43. 53-

Eldor A, Lellouche F and Goldfarb A. (1991): In vivo platelet activation in beta-thalassemia major reflected by increased

platelet-thromboxane

Blood;77:1749–1753.

113

urinary

metabolites.

 54-

REFERENCES El-Hazmi MA, Al-Swailem A and AL-Fawaz I (1994): Diabetes mellitus in children suffering from beta-thalassemia. J Trop Pediatr; 40: 261-267.

55-

Emery DW, Yannaki E, Tubb J, NishinoT, Li Q and Stamatoyannopoulos G.

(2002): Development of virus

vectors for gene therapy of beta chain hemoglobinopathies: flanking with a chromatin insulator reduces gamma-globin gene silencing in vivo. Blood; 100:2012-9. 56-

Fairbanks

VF

and

Beutler

E

(1995):

Iron

metabolism.In:William Hematology, Beutler E., Lichtman MA and Collar BS (eds), fifth edition , McGraw –Hill Publishing company, New York pp, 369-380 . 57-

Fang J, Huang S and Chen C. (2004): Umbilical cord blood

transplantation

in

Chinese

children

with

beta-

thalassemia. J Pediatr Hematol Oncol;26:185-9. 58-

Festa A, D'Agostino R Jr, Hanley AJ, Karter AJ, Saad MF and Haffner SM. (2004): Differences in insulin resistance in nondiabetic subjects with isolated impaired glucose tolerance

or

isolated

impaired

fasting

glucose. Diabetes;53(6):1549-55. 59-

Fibach E. (2001): Cell culture and animal models to screen for promising fetal hemoglobin- stimulating compounds. Semin Hematol; 38: 374-81.

60-

Forget

BG

(2000):

Thalassemia

114

syndromes.

In



REFERENCES Hematology. Basic Principles and Practice. Hoffman R, Edward JB, Sanford JS et al. (eds). 3rd edition. Churchill Livingstone. A Division of Harcourt Brace & Company. New York, Edinburgh, London Philadelphia, San Francisco, chapter 29, pp 486-506.

61-

Forget

BG.

(2000):

Thalassemia

Syndromes.

In:

Hematology: Basic Principles and Practice485-509. 62-

Forget BG. (2001): Molecular genetics of the human globin genes. In: Steinberg MH, Forget BG, Higgs DR, Nagel RL, eds. Disorders of haemoglobin. Cambridge: Cambridge University Press,:117–130.

63-

Forget BG, Pearson HA (1995): Hemoglobin synthesis and thalassemia, In Handin RI,Lux SE, Stossel TP. Blood principles and practice of hematology first ed., JB lippincott Company, Philadelphia,1525.

64-

Franchini M and Veneri D. (2004): Iron-chelation therapy: an update. Hematol J;5:287- 92.

65-

Fucharoen S and Winichagoon P. (2000): Clinical and hematologic aspects of hemoglobin E beta-thalassemia. Curr Opin Hemat; 7: 106-112

66-

Gagliardino JJ. (2005): Physiological endocrine control of energy homeostasis and postprandial blood glucose levels. Eur Rev Med Pharmacol Sci; 9:75–92.

115

 67-

REFERENCES Galanello R, Piras S and Barella S. (2001): Cholelithiasis and Gilbert's syndrome in homozygous ß-thalassemia. Br J Haematol; 115: 926–928.

68-

Ganavello R (1995) : Molecular basis of thalassemia major. Int J Pediat Hematol Oncol.,2:383-396.

69-

Ganz T. (2003): Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood;102:783-8.

70-

Genuth S, Alberti KG, Bennett P and Buse J. (2003): The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care; 26:3160–3167.

71-

Gerich JE, Meyer C, Woerle HJ and Stumvoll M. (2001): Renal gluconeogenesis: its importance in human glucose homeostasis. Diabetes Care; 24:382–391.

72-

Gutt M. Davis CL. Spitzer SB., Llabre M.,Kumr M., Czarnecki

EM.

Scheiderman

N,Skylar

Js.,Marks

JB.(2000):Validation of the insulin sensitivity index [ ISI (0,120)]: comparison with other measures. Diabetes Res Clin Pract.;47:166-184 73-

Haffner SM., Kennedy E., Gonzalez C., Stern MP., Miettinen H.(1996): A prospective analysis of the HOMA model. The Mexico City Diabetes Study. Diabetes Care; 19:1138-1141.

116

 74-

REFERENCES

Hall JG, Martin PL, Wood S and Kurtzberg J. (2004): Unrelated umbilical cord blood transplantation for an infant with

beta-thalassemia

major.

J

Pediatr

Hematol

Oncol;26:382-5.

75-

Harris MI, Flegal KM and Cowie CC. (1998): Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition

Examination

Survey,

1988-1994. Diabetes

Care;21(4):518-24. 76-

Hassan M.Y: Thalassemia.e Medicine J. 2001; 2 (11): 142.

77-

Herman WH, Hoerger TJ and Brandle M. (2005): The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Ann Intern Med;142(5):323-32.

78-

Hershko C, Link GM, Konijn AM and Cabantchik ZI. (2005): Iron chelation therapy. Curr Hematol Rep;4:110-6.

79-

Higgs DR, Thein SL and Woods WG. (2001): The molecular pathology of the thalassemias. In: Weatherall DJ, Clegg B, eds. The thalassemia syndromes. 4th ed. Oxford,

117



REFERENCES England: Blackwell Science:133-91.

80-

Hoffbrand AV, Cohen A and Hershko C. (2003): Role of deferiprone in chelation therapy for transfusional iron overload. Blood;102: 17-24.

81-

Honig GR (2000): Hemoglobin disorders in: Nelson Textbook of pediatrics. Behrman RE, Kliegman RM and Tenson HB (eds). Sixteenth Edition WB Saunders Company. Philadelphia, London Toronto ,Montereal Sydney ,Tokyo,p .1478.

82-

Hovav T, Goldfarb A and Artmann G. (1999): Enhanced adherence of ß-thalassemia erythrocytes to endothelial cells. Br J Haematol;106:178–181.

83-

Hussein IR, Temtamy SA and el-Beshlawy A. (1993): Molecular characterization of beta-thalassemia in Egyptians. Hum Mutat;2:48–52.

84-

Iannone R, Casella JF and Fuchs EJ. (2003): Results of minimally toxic nonmyeloablative transplantation in patients with sickle cell anemia and beta-thalassemia. Biol Blood Marrow Transplant;9:519-28.

85-

Imren S, Fabry ME and Westerman KA. (2004): Highlevel

beta-globin

expression

and

preferred

intragenic

integration after lentiviral transduction of human cord blood stem cells. J Clin Invest;114:953-62. 86-

Jensen CE, Tuck SM and Agnew JE. (1998): High

118



REFERENCES prevalence of low bone mass in thalassaemia major. Br J Haematol;103:911–915.

87-

Jimmy PS, Kai HL, and Meng-Yao LU (2001): Abnormal Glucose

Tolerance

in

Transfusion-Dependent

β

-

Thalassemic Patients. Diabetes Care 24:850–854. 79- Jones TW, Boulware S, Caprio P,Merkel SA and Amiel HA (1993): Correction of hyperinsulinemia by glyburide treatment in nondiabetic patients with thalassemia major pediatr Res; 33 :497452. 88-

Kahn SE. (2003): The relative contributions o to the pathophysiology of type 2 diabetes. Diabetologia; 46:3–19.

89-

Kattamis CA and Kattamis AC. (1995): Management of thalassemias: substitution,

growth vitamin

and

development,

supplementation,

and

hormone vaccination.

Semin Hematol;32:269–279. 90-

Kazazinan HH (1990): The thalassemia syndromes, molecular

basis

and

prenatal

diagnosis.

Semin

Hematol.,27:209-11. 91-

Khalifa AS ,Baffico M, Hesmat NM, et al.(1995): Relationship between the hematological phenotype and the type of beta-thalassemia mutation in Egyptian children. Egypt J Hematol.,20(2):130-137.

92-

Khalifa AS, Salem M, Mounir E, El-Tawil MM, El-Sawy M and Abd Al-Aziz MM (2004): Abnormal glucose tolerance in

119



REFERENCES Egyptian beta-thalassemic patients: Possible association with genotyping. Pediatr Diabetes; 5: 126-132.

93-

Kong Y, Zhou S, and Kihm AJ. (2004): Loss of alphahemoglobin-stabilizing protein impairs erythropoiesis and exacerbates β-thalassemia. J Clin Invest;114:1457- 66.

94-

Kowdley KV and Kaplan MM (1998): Iron-chelation therapy with oral deferiprone; toxicity or lack of efficacy? N Eng J Med; 339: 468-469.

95-

Krentz AJ and Bailey CJ. (2005): agents:

current

role

in

Oral antidiabetic

type

2

diabetes

mellitus. Drugs;65(3):385-411. 96-

Krishnamurti L, Abel S, Maiers M and Flesch S. (2003): Availability of unrelated donors for hematopoietic stem cell transplantation

for

hemoglobinopathies.

Bone

Marrow

Transplant ; 31: 547-50. 97-

Kuypers FA and de Jong K. (2004): The role of phosphatidylserine

in

recognition

and

removal

of

erythrocytes. Cell Mol Biol;50:147-58.

98-

La Nasa G, Giardini C and Argiolu F. (2002): Unrelated donor bone marrow transplantation for thalassemia: the effect of extended haplotypes. Blood;99:4350-6.

99-

Labropoulou-Karatza C, Goritsas C, and Repandi M

120



REFERENCES (1999): High prevalence of diabetes mellitus among adult βthalassemic patients with chronic hepatitis C. Eur J Gastroenterol Hepatol; 11: 1033-1036.

100-

Lacerra G, Sierakowska H and Carestia C. (2000): Restoration of hemoglobin A synthesis in erythroid cells from peripheral blood of thalassemic patients. Proc Natl Acad Sci USA;97:9591-6.

101-

Ladis V, Theodorides C, Palamidou F, Frissiras S, Berdousi H and Kattamis C. (1998): Glucose disturbances and regulation with glibenclamide in thalassemia. J Pediatr Endocrinol Metab; 11 (Suppl. 3):871–878.

102-

Lanng S (1997): Glucose intolerance in cystic fibrosis. Dan Med Bull; 44: 23- 39.

103-

Lasco A, Morabito N and Gaudio A. (2001): Effects of hormonal replacement therapy on bone metabolism in young adults with beta-thalassemia major. Osteoporos Int;12:570– 575.

104-

Loasombaty V, Giardina OJ, Omri LL et al., (2001) : Clinical and Hematological features of codon 17.Mutation of beta thalassemia. Eur J Haematol.,66(2) :126-9.

105-

Locatelli F, Rocha V and Reed W. (2003): Related umbilical

cord

blood

transplantation

in

patients

thalassemia and sickle cell disease. Blood;101:2137-43.

121

with

 106-

REFERENCES Lorey F. (2000): Asian immigration and public health in California: thalassemia in newborns in California. J Pediatr Hematol Oncol; 22: 564–546.

107-

Louise LO and Singer ST (2002) : Thalassemia :current approach to an old disease.Hematol Oncol Pediat. Clin N Am., Pediatr , Part II 49(6) : 1278-1303.

108-

Loukopoulos D. (1996): Current status of thalassemia and the sickle cell syndromes in Greece. Semin Hematol;33:76– 86.

109-

Lucarelli G, Galimberti M and Polchi P. (1993): Bon marrow

transplantation

in

patients

with

thalassemia

responsive to iron chelation therapy. N Engl J Med; 329(12): 840-845. 110-

Lukens TN (1993): The thalassemia and related disorders in wintrob's clinical hematology, ninth edition : Lee GR, Brithhell TC, Forester J, Athens JW and Lukens JN (eds),Harcourt Health Science, Philadelphia; pp:1102-1105.

111-

Lukens TN (1999): The thalassemia and related disorders. Quantitative disorders of hemoglobin synthesis. In : wintrob's clinical hematology.Richard G, John F,Frixos P et al .(eds), tenth edition, volume 1, Philadelphia WB Saunders,pp. 14051446.

112-

Malik P and Arumugam PI (2005): Gene Therapy for {beta}-Thalassemia. Hematology (Am Soc Hematol Educ Program) 2005; 45-50

122

 113-

REFERENCES

Mangiagli A, Italia S, De SV and Campisi S (2002): Impaired glucose homeostasis in young adult thalassmic patients: a pilot Study with acarbose. j Pediatr Endocrinol Metabol; 15 (2): 205- 210.

114-

Manodori AB, Barabino GA, Lubin BH and Kuypers FA. (2000):

Adherence

of

phosphatidylserine-

exposing

erythrocytes to endothelial matrix thrombospondin. Blood;95: 1293-300. 115-

Matthewas DR.,Hosker JP ., Rudenski AS., Naylor BA., Treacher

DF.,

Turner

RC(1985):Homeostasis

model

assessment : insulin resistance and Beta cell function from fasting

plasma

glucose

and

insulin

concentration

in

man.Diabetologia.28:412-419

116-

Merkel PA, Simonson DC, Amiel SA, Plew G and Person HA (1988): Insulin resistance and hyperinsulinemia in patients with thalassemia major treated by hypertransfusion. N Engl J Med; 318: 809- 814.

117-

Modell B, Khan M and Darlison M. (2000): Survival in beta-thalassaemia major in the UK: data from the UK Thalassaemia Register. Lancet;355:2051-2.

118-

Mohammdian

S.,Bazrafshan

123

HR.,

Nejad



REFERENCES A(2003):Endocrine gland abnormalities in thalassemia major. J of Endocrinol Metab; 16(7):957-964.

119-

Monge L, Pinach S, Caramellino L, Bertero MT and carta Q (2001): The possible role of autoimmunity in the pathogenesis of diabetes in β-thalassemia major. Diabetes Metab; 27: 149- 54.

120-

Moratelli S, De Sanctis V and Gemmati D. (1998): Thrombotic risk in thalassemic patients. J Pediatr Endocrinol Metab;11[Suppl 3]:915–921.

121-

Moreau-Gaudry F, Xia P and Jiang G. (2001): High-level erythroid-specific gene expression in primary human and murine hematopoietic cells with self-inactivating lentiviral vectors. Blood;98: 2664-72.

122-

Old JM, Olivieri NF and Thein SL. (2001): Diagnosis and management of thalassemia. In: Weatherall DJ, Clegg B, eds. The thalassaemia syndromes. 4th ed. Oxford, England: Blackwell Science:630-85.

123-

Olivieri NF, Brittenham GM and McLaren CE. (1998): Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major. N Engl J Med 13; 339(7): 417-23

124-

Olivieri NF. (1999): Medical progress: The β-thalassemias. N Engl J Med;34:99.

125-

Pace BS, Shartava A, Pack-Mabien A, Mulekar M, Ardia

124



REFERENCES A and Goodman SR. (2003): Effects of N-acetylcysteine on dense cell formation in sickle cell disease. Am J Hematol; 73:26-32.

126-

Paik CH, Alavi I, Dunea G and Weiner L. (1970): Thalassemia and gouty arthritis. JAMA;213:296–297.

127-

Papanikolaou G, Tzilianos M and Christakis JI. (2005): Hepcidin in iron overload disorders. Blood;105:4103-5.

128-

Perrotta S, Cappellini MD and Bertoldo F. (2000): Osteoporosis in beta-thalassaemia major patients: analysis of the genetic background. Br J Haematol;111:461–466.

129-

Persons DA and Nienhuis AW. (2003): Gene therapy for the hemoglobin disorders. Curr Hematol Rep;2:348-55.

130-

Piga A, Gaglioti C, Fogliacco E and Tricta F. (2003): Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis. Haematologica;88: 489-96.

131-

Pigon J, Giacca A, Ostenson C-G and Efendie S (1995): Extrahepatic insulin sensitivity is enhanced in sedentary and endurance trained low insulin responders. Am J Physiolo; 286: 1046- 1050.

132-

Pootrakul P, Sirankapracha P and Hemsorach S. (2000): A correlation of erythrokinetics, ineffective erythropoiesis, and erythroid

precursor

apoptosis

thalassemia. Blood;96:2606-12.

125

in

Thai

patients

with

 133-

REFERENCES Pootrakul P, Sirankapracha P and Sankote J. (2003): Clinical trial of deferiprone iron chelation therapy in bthalassaemia / haemoglobin E patients in Thailand. Br J Haematol; 122: 305-10.

134-

Puthenveetil G and Malik P. (2004): Gene therapy for hemoglobinopathies: are we there yet? Curr Hematol Rep;3:298-305.

135-

Puthenveetil G, Scholes J and Carbonell D. (2004): Successful correction of the human beta-thalassemia major phenotype using a lentiviral vector. Blood;104:3445-53.

136-

Quirolo k and

Vinckinsky E (2004): Hemoglobin

disorders in Nelson textbook of pediatrics .Behrman R, Kleigman RM and Tenson, HB (eds) seventeenth ed., Philadelphia, London, Toronto, WB, Saunders,4(54):16231634. 137-

Rachmilewitz

EA

and

Schrier

SL.

(2001):

Pathophysiology of ß thalassemia. In: Steinberg MH, Forget BG, Higgs DR, Nagel RL, eds. Disorders of hemoglobin: genetics,

pathophysiology,

and

clinical

management.

Cambridge: Cambridge University Press, pp:233–251. 138-

Rachmilewitz EA, Weizer-Stern O and Adamsky K. (2005):

Iron and oxidative stress in thalassemia: Eighth

International Cooley’s Anemia Symposium. Ann N Y Acad Sci;1054:1-6.

126

 139-

REFERENCES Rady MS, Baffico M, Khalifa AS, Heshmat NM, elMoselhy S, Sciarratta GV, Hussein IR, Temtamy SA and Romeo G. (1997): Identification of Mediterranean betathalassemia mutations by reverse dot-blot in Italians and Egyptians. Hemoglobin; 21(1):59-69.

140-

Raiola G, Galati MC and De Sanctis V. (2003): Growth and puberty in thalassemia major. J Pediatr Endocrinol Metab;16:Suppl 2:259-66.

141-

Ramachandran A, Snehalatha C and Kapur A (2001): High prevalence of diabetes and impaired glucose tolerance in India. National Urban Diabetes Survery. Diabetologia; 44: 1094- 1101.

142-

Rivella S and Sadelain M. (2002): Therapeutic globin gene delivery using lentiviral vectors. Curr Opin Mol Ther;4:505-14.

143-

Ruggiero L and De Sanctis V. (1998): Multicentre study on

prevalence

of

fractures

in

transfusion-dependent

thalassaemic patients. J Pediatr Endocrinol Metab;11[Suppl 3]:773–778. 144-

Rund D and Rachmilewitz EA. (2001): Pathophysiology of α- and β-thalassemia: therapeutic implications. Semin Hematol;38:343-9.

145-

Saleh M.,Grunbereger G(2001):Hypoglycemia an excuse for poor glycemic control? Clinical Diabetes:19(4):161-167

127

 146-

REFERENCES Schrier SL and Angelucci E (2005): New strategies in the treatment of the thalassemias. Annu Rev Med; 56: 157-71

147-

Scott MD, Rouyer-Fessard P and Ba Ms. (1992): α- and ß-Haemoglobin chain induced changes in normal erythrocyte deformability. Comparison to ß-thalassemia intermedia and Hb H disease. Br J Haematol;80:519–526.

148-

Seeman E and Delmas PD. (2001): Reconstructing the skeleton with intermittent parathyroid hormone. Trends Endocrinol Metab; 12:281–283.

149-

Senok AC, Li K and Nelson EA. (1997): Invasion and growth of Plasmodium falciparum is inhibited in fractionated thalassemic

erythrocytes.

Trans

Roy

Soc

Trop

Med

Hyg;91:138–143. 150-

Singer ST, Sweeters N, Vichinsky EP, Wagner AJ and Rachmilewitz EA. (2003): A dose-finding and safety study of darbepoietin alfa (erythropoiesis stimulating protein) for the treatment of anemia in patients with thalassemia intermedia. Blood;102:268a.abstract.

151-

Sodani P, Gaziev D and Polchi P. (2004): New approach for bone marrow transplantation in patients with class 3 thalassemia aged younger than 17 years. Blood;104:1201-3.

152-

Sougleri M.,Labropoulou-Karatza C., Paraskevopoulo P. Fragopanagou H., Alexandrides T(2001):Chronic Hepatitis C virus infection without induces insulin resistance in patients

128



REFERENCES with [beta] –thalassemia major.Eur J Gastroenterol Hepatol; 13(10):1195-1199

153-

Steinberg MH, Barton F and Castro O. (2003): Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA;289:1645-51.

154-

Stumvoll

M.,

Mitrakou

A.,

Pimenta

W.,

Jenssen

T(2000):use of the oral glucose tolerance test to assess insulin release and insulin sensitivity.Diabetes Care; 23:295301 155-

Teitz NW(1986):Specimen collection and processing : sources of biological variation. Text book of clinical chemistry; 478-518,W.B. Saunders Co. Philadelphia.

156-

Tesoriere L, D’Arpa D and Butera D. (2001): Oral supplements of vitamin E improve measures of oxidative stress in plasma and reduce oxidative damage to LDL and erythrocytes in β-thalassemia intermedia patients. Free Radic Res;34:529-40.

157-

Testa U. (2004): Apoptotic mechanisms in the control of erythropoiesis. Leukemia; 18:1176-99.

158-

Thein SL (1998): Beta thalassemia. Baillieres Clin Haematol., 11(1): 91-129.

159-

Vacek MM, Ma H, Gemignani F, Lacerra G, Kafri T and Kole R. (2003): High-level expression of hemoglobin A in human thalassemic erythroid progenitor cells following

129



REFERENCES lentiviral

vector

delivery

of

an

antisense

snRNA.

Blood;101:104-11. 160-

Van de Velde H, Georgiou I and De Rycke M (2004): Novel

universal

approach

for

preimplantation

genetic

diagnosis of beta-thalassaemia in combination with HLA matching of embryos. Hum Reprod;19:700-8. 161-

Vendrame F and Gottlieb PA. (2004): Prediabetes: prediction and prevention trials. Endocrinol Metab Clin North Am; 33:75–92.

162-

Vetter B, Neu-Yilik G, Kohne E et al. (2000): Dominant beta –thalassemia : a highly unstable Hemoglobin is caused by a novel 6Kb deletion of the beta- globin gene, British Journal of Hematology, 108: 176-181.

163-

Voskaridou E and Terpos E. (2004): New insights into the pathophysiology and management of osteoporosis in patients with beta thalassaemia. Br J Haematol;127:127-39.

164-

Voskaridou E, Douskou M and Terpos E. (2004): Magnetic resonance imaging in the evaluation of iron overload in patients with β- thalassemia and sickle cell disease. Br J Haematol;126:736-42.

165-

Voskaridou E, Kyrtsonis MC and Terpos E. (2001): Bone resorption is increased in young adults with thalassaemia major. Br J Haematol;112:36–41.

166-

Weatherall DJ (1994): The thalassemia in :Molecular basis

130



REFERENCES of blood diseases. Stomatu-Yannopoulos G, Nienhus AW, Majerus PW et al. (eds), second edition WB Saunders, Philadelphia,p. 157-205.

167-

Weatherall DJ (1998): Pathophysiology of thalassemia Baillieres Clin Hematol.,11(1):127-96.

168-

Weatherall DJ and Clegg JB, Higgs DR and Wood WG (1995): The hemoglobinopathies. IN: the metabolic and molecular basis of inherited disease. Vol.III ed. By Scriver CR, Beaud et al, Sly WS, Valle D, Stanbuy JW, Wyngarden JB and Friedrickson DS. Seventh edition , McGraw-Hill Inc., 503-9.

169-

Weatherall DJ and Clegg JB. (1996): Thalassaemia- a global public health problem. Nat Med;2:847-9.

170-

Weatherall DJ and Clegg JB. (2001): The Thalassaemia Syndromes. Oxford: Blackwell Science, 2001.

171-

Weatherall DJ. (2001): Phenotype-genotype relationships in monogenic disease: lessons from the thalassemias. Nat Rev Genet; 2:245-55.

172-

Whipple GH and Bradford WL. (1936): Mediterranean disease- thalassemia (erythroblastic anemia of Cooley): associated

pigment

abnormalities

simulating

hemochromatosis. J Pediatr;9:279-311.

173-

Wiener E, Wanachiwanawin W and Chinprasertsuk S.

131



REFERENCES (1996): Increased serum levels of macrophage colonystimulating factor (M-CSF) in alpha- and beta-thalassemia syndromes:

correlation

with

anaemia

and

monocyte

activation. Eur J Haematol;57:364–369. 174-

Wonke B (1995): Glucose intolerance and diabetes in thalassemia major. In: Endocrine disorders in thalassemia. Ando S, Bancati C (eds). Ulm, Germany, Springer; 65- 67.

175-

Wonke B. (1998): Bone disease in ß-thalassaemia major. Br J Haematol;103:897–901.

176-

World Health Organization (1999): Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications: Report of a WHO Consultation. Part 1: Diagnosis and Classification of Diabetes Mellitus. Geneva, World Health Org., 1999

177-

Xiao W and Oefner PJ. (2001): Denaturing highperformance

liquid

chromatography:

a

review.

Hum

Mutat;17:439–474. 178-

Zoueva OP and Rodgers GP. (2004): Inhibition of beta protein 1 expression enhances betaglobin promoter activity and beta-globin mRNA levels in the human erythroleukemia (K562) cell line. Exp Hematol;32:700-8.

179-

Zuppinger K, Molinari B, Girt A and Imbach P (1979): Increased risk of DM in beta-thalassemia major due to iron overload. Helv Pediatr Acta; 34: 197-207.

132



REFERENCES

133